

- Blood vessel(s) (*Continued*)
 hyperactivity of, disorders of, 513-514
 in inflammation
 acute, 73-75
 chronic, 94
 myocardial vessel vasospasm, 514
 pathology of vascular intervention for, 520-521
 Raynaud phenomenon, 513-514, 513f
 response to injury of, 485-487
 structure and function of, 483-485, 485b
 tumor(s) of, 515-520
 benign, 516-518, 517b
 bacillary angiomatosis as, 517-518
 glomus tumor as (glomangioma), 517
 hemangioma as, 516
 lymphangiomias as, 516-517
 intermediate-grade (borderline) tumors of, 518-519
 hemangiioendothelioma, 519
 Kaposi sarcoma as, 518
 malignant, 519-520
 angiosarcoma, 519, 520f
 hemangiopericytoma, 520
 vascular anomalies, 485
 vasculitis of, 505-513
 Behçet disease, 511
 Churg-Strauss syndrome, 511
 giant cell, 507-508
 immune complex-associated, 506-507
 infectious, 513
 Kawasaki diseases as, 510
 microscopic polyangiitis, 510-511
 noninfectious, 506-513
 polyarteritis nodosa, 509-510
 Bloodstream expression sites, 394
 Bloodstream parasites, of African trypanosomiasis, 394, 394f
 Bloom syndrome, 314-315
 "Blue bloaters", 679
 Blue-dome cysts, of breast, 1048, 1048f
 Blue nevus, 1144t
 Body mass index (BMI)
 and malnutrition, 433
 and obesity, 444
 Boil, 364b
 Bone, mineralization of, 440, 440f
 Bone disease(s), in hyperparathyroidism, 1103
 Bone-forming tumors, 1197-1200, 1207b
 osteoblastoma, 1197, 1198b
 osteoid osteoma, 1197, 1198b, 1198f
 osteosarcoma, 1198-1200, 1198f, 1199f, 1199b
 Bone marrow, 581b-582b
 embolization, 1266f
 in sarcoidosis, 693b-694b
 Bone marrow transplantation, 865
 Bone matrix, 1180
 proteins of, 1180t
 Bone morphogenetic protein receptor type 2 (BMPR2), 699-700
 Bone morphogenic proteins (BMPs), 1182
 Bones, 1179-1226
 acquired disorders of, and cartilage, 1187-1193, 1193b
 basic structure and function of, 1180-1183
 cells of, 1180-1181
 development of, 1181-1182
 developmental disorders of, and cartilage, 1183-1187, 1184t, 1187b
 degradation of macromolecules, diseases associated with defects in, 1187
 Bones (*Continued*)
 extracellular structural proteins, defects in, 1185-1186
 hormones and signal transduction proteins, defects in, 1184-1185
 metabolic pathways, defects in, 1186-1187
 nuclear proteins and transcription factors, defects in, 1184
 fractures of, 1193-1194
 homeostasis and remodeling of, 1182-1183, 1182f, 1183f
 osteomyelitis of, 1195-1196, 1195b, 1196f
 osteonecrosis of, 1194-1195, 1194b, 1194t, 1195f
 tumors and tumor-like lesions, 1196-1207, 1197t, 1207b
 Border zone ("watershed") infarcts, 1264
Bordetella pertussis, 368
Borrelia burgdorferi, 381, 1214
 Botox, 1236-1237
 Botulism, 382, 1236-1237
 Bowen disease, of penis, 971, 971f
 Bowenoid papulosis, 971, 1175
 Bowman layer, 1325
 Brachydactyly, 1184t
 Bradykinin, in inflammation, 89
 BRAF gene, oncogenic, 286-287
 Brain abscess, 1273-1274, 1273b, 1274f
 Brain-derived neurotrophic factor (BDNF), in energy balance, 445
 Brain edema, 115
 Brain injury
 concussion, 1259
 contusions as, 1259-1260
 coup and contrecoup, 1260
 diffuse axonal, 1261
 lacerations as, 1259-1260
 parenchymal, 1259-1261
 perinatal, 1258-1259
 sequelae of, 1262-1263
 skull fractures as, 1259
 vascular, 1261-1262
 Brain stem, 472
 Brainstem glioma, 1309
 Branchial cyst, 741
 BRCA1, 315
 and breast cancer, 1054, 1054t
 BRCA2, 315
 and breast cancer, 1054, 1054t
 and prostate cancer, 985
 Breakdown products, lipid, 49
 Breast, 1043-1071
 anatomy of, 1043, 1044f
 developmental disorders of, 1044-1045
 fibroadenoma, of, 272f
 invasive ductal carcinoma of, 272f
 life cycle changes in, 1044f
 male, 1066
 supernumerary, 1044
 Breast Cancer Risk Assessment Tool (BCRAT), 1053-1054
 Breast carcinoma, 1051-1057
 basal-like, 1055, 1056f
 comedo, 1057, 1058f
 contralateral, 1053
 ductal
 invasive (infiltrating), 1060-1064, 1061f
 in situ, 1057-1058, 1058f, 1059f
 epidemiology of, 1052-1054, 1057b
 estrogen receptors in, 1052, 1068
 etiology and pathogenesis of, 1054-1057, 1057b
 Breast carcinoma (*Continued*)
 gene expression profiling for, 1055, 1060, 1061f
 grading of, 1064f, 1068
 HER2-positive, 1055-1056, 1056f, 1060-1062, 1062f, 1068
 hereditary, 1054, 1054t
 incidence of, 1052-1054, 1052f
 inflammatory, 1067
 invasive (infiltrating), 1060-1064, 1060t
 ductal (no special type), 1060, 1063f
 lobular, 1065
 papillary, 1065
 lobular
 invasive, 1065
 in situ, 1059-1060, 1059f
 locally advanced, 1067
 luminal A, 1060
 luminal B, 1060
 lymphovascular invasion by, 1067
 male, 1066
 medullary, 1065, 1065f
 metaplastic, 1066
 metastatic, 1066
 molecular mechanisms of carcinogenesis and tumor progression, 1055-1057
 mucinous (colloid), 1065, 1065f
 no special type, 1060, 1063f
 occult, 1064
 oral contraceptives and, 421
 papillary, 1065
 prognostic and predictive factors in, 1066-1068, 1068b
 proliferative rate of, 1068
 risk factors for, 1053-1054
 screening for, 1045, 1045f, 1052
 in situ, 1057-1060
 ductal, 1057-1058, 1058f, 1059f
 lobular, 1059-1060, 1059f
 sporadic, 1055
 staging of, 1067f, 1068t
 susceptibility genes for, 1054, 1054t
 triple negative, 1062
 tubular, 1065, 1065f
 tumor size in, 1067
 types of, 1057-1068, 1068b
 Breast changes, nonproliferative (fibrocystic), 1048, 1051t
 Breast cysts, 1048, 1048f
 Breast density, and breast cancer, 1053
 Breast disease
 benign epithelial, 1048-1051, 1051b
 adenosis as, 1048
 sclerosing, 1049, 1049f
 atypical ductal hyperplasia as, 1050, 1051f
 atypical lobular hyperplasia as, 1050, 1051f
 clinical significance of, 1051, 1051t
 complex sclerosing lesion as, 1049, 1050f
 cysts as, 1048, 1048f
 epithelial hyperplasia as, 1049, 1049f
 fibrosis as, 1048
 lactational adenomas as, 1048
 nonproliferative (fibrocystic) changes as, 1048, 1051t
 papillomas as, 1049, 1050f
 proliferative changes as
 with atypia, 1050-1051, 1051t
 without atypia, 1048-1050, 1051t
 calcifications due to, 1046
 carcinoma as. *See* Breast carcinoma
 clinical presentations of, 1045-1046, 1045f
 densities due to, 1046